Inicio › Cáncer metastásico › Florida › Miami
Ensayos clínicos de Cáncer metastásico en Miami, FL
24 estudios para Cáncer metastásico buscan participantes en centros de Miami y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
ReclutandoFase 2
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
ReclutandoFase 3
- Miami Cancer Institute, Miami
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
ReclutandoFase 3
- Research Site, Miami
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
ReclutandoFase 2
- Sylvester Comprehensive Cancer Center, Miami
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
ReclutandoFase 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
ReclutandoFase 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
ReclutandoFase 1/2
- Sylvester Comprehensive Cancer Center - Miami, Miami
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
ReclutandoFase 1
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
ReclutandoFase 3
- Miami Cancer Institute at Baptist Health, Inc., Miami
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- University of Miami, Miami
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
ReclutandoFase 3
- University Of Miami-SCCC-Miami, Miami
- University of Miami_SCCC - Kendall, Miami
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
ReclutandoFase 3
- Research Site, Miami
- Research Site, Miami
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
ReclutandoFase 1
- Sylvester Comprehensive Cancer Center, Miami
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
ReclutandoFase 3
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
ReclutandoFase 1/2
- University of Miami; Sylvester Cancer Center, Miami
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
ReclutandoFase 2/3
- Sylvester Comprehensive Cancer Center, Miami
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
ReclutandoFase 2/3
- Sylvester Comprehensive Cancer Center, Miami
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
ReclutandoFase 1
- Sylvester Comprehensive Cancer Center, Miami
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
ReclutandoFase 1
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
ReclutandoFase 3
- University of Miami, Miami
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Miami
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
ReclutandoFase 3
- Miami Cancer Institute, Miami
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
ReclutandoFase 1
- University of Miami, Miami
Ensayos de Cáncer metastásico en otras ciudades
- Houston, TX104 estudios
- New York City, NY93 estudios
- Nashville, TN70 estudios
- Boston, MA63 estudios
- Los Angeles, CA57 estudios
- St. Louis, MO54 estudios
- Arlington, VA53 estudios
- Philadelphia, PA46 estudios
- Chicago, IL45 estudios
- San Antonio, TX44 estudios
- Washington, DC43 estudios
- Dallas, TX42 estudios
Otros estudios en Miami
- Cáncer de seno42 estudios
- Cáncer (todos los tipos)36 estudios
- Cáncer de pulmón de células no pequeñas31 estudios
- Cáncer de próstata27 estudios
- Obesidad27 estudios
- Leucemia mielógena aguda24 estudios
- Cáncer de ovario23 estudios
- Sobrepeso23 estudios
- Mieloma múltiple21 estudios
- Colitis ulcerativa21 estudios
- Enfermedad de Alzheimer20 estudios
- Cáncer de pulmón20 estudios
De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.